Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: The role of albumin in the model

Hematology

Volumn 12, Issue 6, 2007, Pages 527-531

  Mihou, Dimitra ^a   Katodritou, Eirini ^a   Zervas, Kostas ^a  

^a THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

Albumin; Beta 2 microglobulin; Myeloma; Staging

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER DIAGNOSIS; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISEASE MODEL; FEMALE; GENE FUNCTION; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; SERUM ALBUMIN; SURVIVAL RATE;

EID: 35748940299     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330701384161     Document Type: Article

References (16)

1. Durie, BGM and Salmon, SE (1975) A clinical staging system for multiple myeloma. Cancer, 36, pp. 842-854.
2. Greipp, PR (1992) Advances in the diagnosis and management of myeloma. Sem Hematol, 29, pp. 24-45.
3. Gassman, W., Pralle, H., Haferlach, T., Pandurevic, S., Graubner, M. and Schmitz, N. (1985) Staging systems for multiple myeloma: A comparison. Br J Haematol, 59, pp. 703-711.
4. Attal, M., Harousseau, JL, Stoppa, AM, Sotto, JJ, Fuzibet, JG and Rossi, JF (1996) prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med, 335, pp. 91-97.
5. 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood, 72, p. 219.
6. Bataille, R., Durie, GM, Grenier, J. and Sany, J. (1986) Prognostic factors and staging in multiple myeloma. A reappraisal. J Clin Oncol, 4, pp. 80-87.
7. Jacobson, JL, Hussein, MA, Barlogie, B., Durie, BGM and Crowley, JJ (2003) A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol, 122, pp. 441-450.
8. Greipp, PR, Miguel, J San, Durie, BGM, Crowley, J., Barlogie, B. and Bladé, J. (2005) International staging system for multiple myeloma. J Clin Oncol, 23, pp. 3412-3420.
9. 2M alone. Blood, 102:11
10. Bataille, R., Durie, BG and Grenier, J. (1983) Serum beta2 microglobulin and survival duration in multiple myeloma: A simple reliable marker for staging. Br J Haematol, 55, pp. 439-447.
11. Bjerrum, OW and Plesner, T. (1985) Beta-2 microglobulin: A valuable parameter of stage, prognosis and response to treatment in myelomatosis. Scand J Haematol, 35, pp. 22-25.
12. Cuzick, J., De Stavola, BL, Cooper, EH, Chapman, C. and Lennan, IC Mac (1990) Long-term prognostic value of serum β2 microglobulin in myelomatosis. Br J Haematol, 75, pp. 506-510.
13. Bataille, R., Grenier, J. and Sany, J. (1984) Beta-2-microglobulin in myeloma: Optimal use for staging, prognosis and treatment - a prospective study of 160 patients Blood, 63, pp. 468-476.
14. Bernier, GM, Cohen, RJ and Conrad, ME (1968) Microglobulinemia in renal failure. Nature, 218, pp. 598-599.
15. Bataille, R., Jourdan, M., Zhang, XG and Klein, B. (1989) Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest, 84, pp. 2008-2011.
16. Lichtenstein, A. and Fady, C. (1995) Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol, 162, pp. 248-255.